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Abstract: The third-generation aromatase inhibitors (AIs), letrozole, anastrozole and exemestane, 
are becoming the ﬁ  rst choice endocrine drugs for post-menopausal women with breast cancer, 
since they present greater efﬁ  cacy when compared with tamoxifen in both adjuvant and metastatic 
setting. In particular, several large and well designed trials have suggested an important role for 
AIs in the adjuvant treatment of postmenopausal women with estrogen-receptor positive breast 
cancer either in the upfront, sequential or extended adjuvant mode. Overall, AIs are associated 
with a small but signiﬁ  cant improvement in disease free survival. The expanding use of AIs in 
the treatment of early breast cancer means that individual patients will be exposed to the agents 
for longer durations, making it increasingly important to establish their long-term safety. This 
review focused on the effects of AIs on bone metabolism, serum lipids and cardiovascular risk. 
AIs have adverse effects on bone turnover with a reduction of bone mineral density and an 
increase in the rate of fragility fractures. With respect to tamoxifen AIs present lower thrombotic 
risk and a less favorable impact on lipid proﬁ  le, whereas the true effects on cardiovascular risk 
still remain to be clariﬁ  ed. An adequate monitoring of bone mineral density (BMD) and lipid 
proﬁ  le could be recommended for post-menopausal women candidate to AIs.
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Efﬁ  cacy of aromatase inhibitors
The third-generation aromatase inhibitors (AIs), letrozole, anastrozole and 
exemestane, are now widely accepted as alternatives to tamoxifen as ﬁ  rst-line 
therapy in postmenopausal women with estrogen receptor (ER)-positive advanced 
breast cancer, because of their improved clinical effectiveness (Nabholtz et al 2000; 
Bonneterre et al 2001; Mouridsen et al 2001). Despite the fact that tamoxifen remains 
an effective drug, AIs appear to be superior to this agent as ﬁ  rst-line endocrine therapy 
for metastatic breast cancer also according to a pooled analysis of 8 randomized 
studies (Carlini et al 2005).
The favorable efﬁ  cacy and safety proﬁ  le in the advanced disease has encouraged 
the evaluation of third-generation AIs in the adjuvant setting. Several phase III 
randomized, adjuvant trials have assessed third-generation AIs in comparison with 
tamoxifen or placebo after 5 years or less of tamoxifen therapy. The results of these 
studies in terms of disease-free survival are summarized in Table 1.
The BIG 1–98 (Big International Group) trial addressed whether letrozole in the 
treatment of postmenopausal women with ER positive breast cancer is more effective 
if used as an initial adjuvant therapy or as sequential therapy following adjuvant 
tamoxifen (Thurlimann et al 2005). Five years after randomization, 84.0% of patients in 
the letrozole group and 81.4% in the tamoxifen group were disease-free, corresponding 
to a 19% relative or 2.9% absolute treatment difference. The absolute reduction in Clinical Interventions in Aging 2008:3(4) 648
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cumulative breast cancer relapses also signiﬁ  cantly favored 
letrozole over tamoxifen at the ﬁ  fth year (10.2% vs 13.6%, 
p = 0.0002) (Thurlimann et al 2005; Coates et al 2007).
The ATAC (Arimidex, Tamoxifen Alone or in Combina-
tion) trial compared adjuvant anastrozole with tamoxifen: 
more than 9,000 postmenopausal women were randomly 
assigned to receive anastrozole plus placebo, or tamoxifen 
plus placebo, or anastrozole plus tamoxifen. With a median 
follow-up of 47 months, in comparison to the tamoxifen arm, 
anastrozole resulted in a statistically signiﬁ  cant reduction 
in breast cancer events and an improvement in disease free 
survival (Baum et al 2002).
After completion of 5 years’ adjuvant treatment 
anastrozole signiﬁ  cantly prolonged disease-free survival and 
signiﬁ  cantly reduced distant metastases and controlateral 
breast cancers (ATAC Trialists’ Group 2005). Recently the 
ATAC Trialists’ Group has reported ﬁ  ndings from an analysis 
of 100-month follow-up data. This analysis showed that in 
hormone-receptor positive populations the improvement 
in disease control with anastrozole with respect to tamoxifen 
was maintained for over three years after treatment cessation 
(ATAC Trialists’ Group 2008).
The Intergroup Exemestane Study (IES) randomly 
assigned 4742 women who had received 2 to 3 years of 
tamoxifen to continue tamoxifen for a total of 5 years or to 
receive exemestane in order to complete a 5-year course of 
hormonal therapy. After a median follow-up of 55.7 months, 
the trial demonstrated a significant reduction in events 
(recurrence, contralateral breast cancer, or death) in favor 
of the exemestane arm (Coombes et al 2007).
In the Italian Tamoxifen Anastrazole (ITA) study, 
women who had received 2 to 3 years of tamoxifen were 
randomly assigned to either continue treatment with tamoxi-
fen for a full 5 years or to receive anastrozole. A total of 
448 patients were enrolled: at a median follow-up time of 
64 months, 63 events had been reported in the tamoxifen 
group compared with 39 in the anastrozole group (HR 0.57, 
95% CI 0.38–0.85, p = 0.005). Relapse-free and overall 
survival were also signiﬁ  cantly longer in the anastrozole 
group (Boccardo et al 2006).
The ARNO (ARimidex-Nolvadex) study reported that 
postmenopausal women who have taken tamoxifen for 2 years 
as adjuvant therapy are less likely to experience a recurrence 
of breast cancer and have an improved possibility of survival 
if they switch to anastrozole (Kaufmann et al 2007).
A combined analysis of data from two randomized 
trials with almost identical inclusion criteria was performed 
in the ABCSG/ARNO study. Postmenopausal women 
who had completed 2 adjuvant years of oral tamoxifen 
(20 or 30 mg daily) were randomized to receive 1 mg oral 
anastrozole or tamoxifen (20 or 30 mg daily) for the remain-
der of their adjuvant therapy. A total of 3224 patients were 
included in the analyses: at a median follow-up of 28 months, 
there was a 40% decrease in the risk of an event in the anas-
trozole group as compared with the tamoxifen group (HR 
0.60, 95% CI 0.44–0.81, p = 0.0008) (Jakesz et al 2005).
The MA-17 trial randomly assigned postmenopausal 
women who were completing 5 years of tamoxifen treat-
ment, to receive either letrozole or a placebo for an 
additional 5 years after adjuvant tamoxifen. After a median 
follow-up of  2.4 years, the study was halted by the Data Safety 
Monitoring Board because of signiﬁ  cant reduction in breast 
cancer events in the letrozole group (Goss et al 2005).
Similar results have been reported in the analysis 
of the Austrian Breast Colorectal Cancer Study Group 
(ABCSG)-6a open label trial of extended adjuvant therapy 
with anastrozole for 3 years after completion of 5 years of 
adjuvant tamoxifen, with or without aminoglutethimide. 
Table 1 Efﬁ  cacy of aromatase inhibitors (AIs) expressed as disease free survival in the adjuvant setting
Treatment 
strategy






Upfront ATAC Ana vs Tam 100 15 4.1
BIG 1–98 Let vs Tam 51 19 2.9
Sequential IES Tam→Exe vs Tam 55.7 24 3.3
ARNO Tam→Ana vs Tam 30.1 34 4.2
ABCSG/ARNO Tam→Ana vs Tam 28 40 3.1
ITA Tam→Ana vs Tam 64 44 7.9
Extended adjuvant MA 17 Tam→Let vs Tam →Plb 30 42 4.6
Abbreviations: Ana, anastrazole; Tam, tamoxifen; Let, letrozole; Exe, exemestane; ATAC, anastrazole, tamoxifen alone or in combination (ATAC Trialists’ Group 2008); BIG, 
breast international group (Coates et al 2007); IES, intergroup exemestane study (Coombes et al 2007); ARNO,  arimidex-nolvadex (Kaufmann et al 2007); ABCSG, austrian 
breast cancer study group (Jakesz et al 2005); ITA, italian tamoxifen anastrazole (Boccardo et al 2006); MA 17, (Goss el al 2005).Clinical Interventions in Aging 2008:3(4) 649
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At a medium follow-up of 62.3 months the women who 
received anastrozole had a signiﬁ  cantly reduced risk of 
recurrence compared with women who received no further 
treatment (Jakesz et al 2007).
A recent meta-analysis evaluated the beneﬁ  t in event-free 
and overall survival of AIs after 2 to 3 years of tamoxifen, 
and revealed that the early switch strategy improves survival 
over the standard tamoxifen 5-year treatment. The risk of any 
event is reduced with AIs by 23%, with an absolute beneﬁ  t 
of 3.8% (Bria et al 2006).
Therefore, the available data from randomized adjuvant 
trials in early breast cancer recommend that the optimal 
adjuvant treatment for postmenopausal women with early 
breast cancer should now include AIs as either initial therapy 
or sequential therapy after tamoxifen treatment. Recent 
modeling data suggest that using AIs as upfront adjuvant 
treatment is better than using AIs in sequence after 2 or more 
years of tamoxifen (Cuzick et al 2003).
Finally when used as preoperative (neoadjuvant) 
treatment, AIs showed greater efﬁ  cacy than tamoxifen with 
regard to breast conservation rate but not to clinical response 
rate (Cataliotti et al 2006).
Mechanism of action of AIs
and other hormone therapies
for breast cancer
A comprehensive description of the mechanism of action of 
hormone therapies for breast cancer is present in two recent 
reviews (Jordan 2007; Journè et al 2008).
Although tamoxifen is an inhibitor of breast cancer 
growth, its effects throughout the human body vary and could 
be characterized as having mixed estrogenic properties. Most 
of the estrogenic properties are desirable, eg, preservation of 
bone mineral density in postmenopausal women or decreases 
of low-density lipoproteins, but these partial estrogen agonist 
effects may also be detrimental and a likely cause of the 
increased risk of some toxicities such as thromboembolic 
events and endometrial cancer (Ganz 2001). In contrast, 
fulvestrant is a new estrogen-receptor antagonist, with no 
known agonist (estrogenic) effects, which has recently been 
licensed for treatment of advanced breast cancer in post-
menopausal women (Journé et al 2008). Recent studies have 
reported that about 30% of postmenopausal women with 
advanced breast cancer who had progressed following prior 
antiestrogen therapy, gained clinical beneﬁ  t with fulvestrant 
therapy thus delaying the need for chemotherapy (Journé et al 
2008; Neven et al 2008). Available data suggest that fulvestrant, 
given intermusculary, is well tolerated, with a low incidence 
of treatment-related adverse events and injection-site reactions 
(Neven et al 2008).
Another recent endocrine treatment is represented by 
third-generation AIs which block the estrogen receptor by 
reducing the levels of its ligand, endogenous estrogen. They 
target the aromatase enzyme (a P-450 cytochrome enzyme), 
which converts testosterone and adrenal androgens to 
estradiol and other estrogens (Smith and Dowsett 2003).
AIs are categorized in two types, non-steroidal 
and steroidal, and differ in their modes of interac-
tion with the aromatase-enzymatic complex and its 
inactivation. Non-steroidal AIs, anastrozole and letrozole, 
are imidazole-based and compete with endogenous substrates 
for access to the cytochrome P-450 moiety of aromatase, 
where they form a reversible co-ordinate bond. The steroidal 
AI exemestane is an analogue of androgens which competes 
with the endogenous androstenedione and testosterone for 
access to the cytochrome P450 moiety of aromatase and 
causes irreversible enzyme inhibition.
Molecular differences between anastrozole, letrozole and 
exemestane affect their selectivity for the aromatase enzyme 
and thus their capability in the inhibition of total-body-
aromatization and, as a result, plasma estrogen suppression 
(Budzar and Howel 2001; Smith and Dowsett 2003).
These differences among the different AIs may explain 
the partial non-cross-resistance between steroidal and non 
steroidal AIs which allows the possibility of using exemestane 
after non-steroidal AIs (Ponzone et al 2008).
The shift from tamoxifen to an AI in both the advanced 
and adjuvant setting has challenged the status of tamoxifen 
as the ‘gold standard’ treatment for postmenopausal women 
with hormone-receptor-posistive breast cancer. Therefore, 
the expanding use of AIs in the treatment of early breast 
cancer means that individual patients will be exposed to these 
agents for longer durations, making it increasingly important 
to establish their long-term safety. The aim of this review was 
to focus on the possible different effects of tamoxifen and AIs 
on bone metabolism, lipid proﬁ  le, and cardiovascular disease 
in postmenopausal patients with early breast cancer.
Effects of AIs on bone metabolism
Estrogens play a crucial role in maintaining both normal bone 
turnover and normal bone mass, and therefore long-term 
estrogen deprivation may be associated with the development 
of osteoporosis and increased susceptibility to bone fractures. 
The better efﬁ  cacy of AIs with respect to tamoxifen in breast 
cancer patients is usually explained by the fact that they reduce 
peripheral estrogen concentrations to extremely low levels, Clinical Interventions in Aging 2008:3(4) 650
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while tamoxifen has partial agonist activity. The profound 
estrogen suppression achievable with the third-generation 
AIs could also explain some unfavorable effects on bone 
(Brufsky 2008). Nevertheless, it has been reported that the 
reduction of the low residual levels of serum estradiol to 
virtually undetectable levels in healthy late postmenopausal 
women is associated with further increases in bone resorption 
rate (Heshmati et al 2002). Moreover, the lower levels of 
serum estradiol are associated with the higher rates of bone 
loss and the greater risk of fractures in late postmenopausal 
women (Cummings et al 1998). The complete estrogen depri-
vation may lead to an increased production of the cytokine 
RANKL by stromal cells and increased activity of RANK, 
thus leading to increased numbers of osteoclastic precursors 
and osteoclastogenesis. This, along with the reduction in 
circulating levels of osteoprotegerin, results in an increase in 
the number of mature osteoclasts and consequently increased 
bone breakdown (McCloskey 2006).
Despite the effects of the third generation AIs on bone 
turnover having been reported in several studies, it is difﬁ  cult 
to assess the difference between the three available agents 
in the absence of head-to-head comparisons. A small study 
performed in postmenopausal women with advanced breast 
cancer described signiﬁ  cant increases in markers of bone 
formation and bone resorption after 3 months of anastrozole 
(Bajetta et al 2002).
The bone substudy of the ATAC trial has reported that 
postmenopausal women with early breast cancer, treated 
for 5 years with anastrozole, presented losses of bone 
mineral density (BMD) both at lumbar spine and total hip, 
at year 1 (−2.3% and −1.5%, respectively) at year 2 (−4.0% 
and −3.9%, respectively) and at year 5 (−6.0% and −7.2%, 
respectively) (Eastell et al 2008). On the other hand the 
treatment with tamoxifen was associated to signiﬁ  cant 
increases in both lumbar spine BMD (1.4% at year 1, 2.1% 
at year 2 and 2.8 at year 5) and total hip BMD (0.8 % at 
year 1, 1.2% at year 2 and 0.7% at year 5) (Eastell et al 
2008). In this study one-year treatment with anastrazole 
signiﬁ  cantly increased both bone formation markers (bone 
alkaline phosphatase [bone-ALP] 20% and procollagen 
type-I N terminal propeptide [PNP] 18% respectively) and 
bone resorption markers ( C-telopeptide of type-I collagen 
[CTX] 26% and N-telopetide of type-I collagen [NTX] 15% 
respectively). On the contrary tamoxifen induced a marked 
decrease in both bone resorption markers (CTX: –56% and 
NTX: –52%) and bone formation markers (PINP: –72% 
and bone ALP: –16%). The withdrawal of tamoxifen was 
followed by a tendency of bone markers to return towards 
baseline values in a period of time ranging from a few weeks 
to several months (Eastell et al 2006).
In the adjuvant ATAC trial, although the anastrozole 
safety proﬁ  le was better than that of tamoxifen overall, there 
was an incidence of fractures signiﬁ  cantly higher in the 
anastrozole arm as compared to that in the tamoxifen arm 
(11.0% vs 7%) after a median follow-up of approximately 
33 months (Baum et al 2002).
A recent article by the ATAC Trialists’ Group has reported 
the findings from an analysis of 100-month follow-up 
data. This analysis showed that fracture rates were higher 
in patients receiving anastrozole than in those receiving 
tamoxifen during active treatment [incidence rate ratio (IRR) 
1.55 (1.31–1.83), p   0.001], but were not different after 
treatment was completed [IRR = 1.03 (0.81–1.31), p = 0.79]. 
Therefore, the increase in fracture rates with anastrozole 
seems to be associated only with the active treatment period 
and does not continue after its completion (ATAC Trialists 
Group 2008).
Assuming a baseline annual fracture rate of 17 fractures 
per 1000 healthy postmenopausal women, survivors of breast 
cancer not treated with adjuvant hormonal therapy have a 
relative fracture risk of 1.15 (20 fractures per 1000 women). 
Based on the ATAC trial, patients with breast cancer 
treated with anastrozole have a relative fracture risk of 
1.36 (23 fractures per 1000 women). This means 2 additional 
fractures per year in 300 postmenopausal women with early 
breast cancer. In contrast, patients treated with tamoxifen have 
a relative fracture risk of only 0.91, suggesting that tamoxifen 
may have bone-protective effects (Brufsky 2008).
The Italian Tamoxifen Anastrozole (ITA) study suggested 
no statistically signiﬁ  cant difference in fracture risk after a 
median follow-up of 36 months between the postmenopausal 
women with early breast cancer switched from tamoxifen 
to anastrozole and those who continued taking tamoxifen 
(Boccardo et al 2006).
In the MA-17 trial, at a median follow-up of 1.9 years there 
were more cases of newly diagnosed osteoporosis in the letro-
zole group compared with the placebo group (5.8% vs 4.5%); 
fractures were more frequent in the letrozole group (3.6% 
vs 2.9%), but the difference was not statistically signiﬁ  cant. 
Since MA-17 underwent an early termination because of 
the positive results of disease-free survival, some questions 
regarding the long term effects of letrozole on bone remain 
unanswered (Goss et al 2005).
Letrozole has also recently been shown to result in signiﬁ  -
cantly greater loss of  BMD at total hip (−3.6% vs −0.71% for 
placebo; p = 0.44) and lumbar spine (−5.3% vs −0.70%  for Clinical Interventions in Aging 2008:3(4) 651
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placebo; p = 0.008) after 2 years of treatment in patients with 
breast cancer who had previously received 5 years of adjuvant 
tamoxifen therapy (Perez et al 2006). Moreover, the results of 
the BIG 1-98 study indicate a statistically signiﬁ  cant increase 
in fracture number in the letrozole arm with respect to the 
tamoxifen arm (9% vs 6%) (Viale et al 2007).
On the basis of experimental studies exemestane, due to its 
steroidal structure, was expected to be less detrimental to bone 
with respect to the non-steroidal anastrozole and letrozole. The 
effects of 24 months of treatment with exemestane, anastro-
zole and letrozole on the serum and urine levels of markers 
of bone turnover were recently compared in 84 healthy 
postmenopausal women. Bone resorption markers, such as 
NTX, were increased to the greatest extent by letrozole, while 
exemestane was associated with increased serum levels of 
the bone formation marker serum PINP (Goss et al 2007). 
This ﬁ  nding suggests a speciﬁ  c bone formation effect of 
exemestane with respect to other Ais, and this was attribuited 
to a possible androgenic activity of exemestane.
A study carried out in postmenopausal women with 
early breast cancer demonstrated that a 2-year treatment 
with exemestane signiﬁ  cantly increased both the mark-
ers of bone resorption (CTX: 35% and NTX: 13.7%) and 
of bone formation (PINP 44.1% and bone-ALP 51.7%) 
(Lonning et al 2005). Exemestane induced a non signiﬁ  cant 
increase in the mean annual rate of BMD loss at lumbar spine 
with respect to placebo (2.17% vs 1.84%) and a slightly 
signiﬁ  cant increase in femoral neck BMD (2.72% vs 1.48%; 
p = 0.02) (Lonning et al 2005).
Two recent reports described that the switching of 
postmenopausal women with early breast cancer from tamoxi-
fen to exemestane causes a marked increase in bone turnover 
markers with a consequent reduction in BMD (Gonnelli et al 
2007; Coleman et al 2007). In the ﬁ  rst study, at the end of 1-year 
treatment with exemestane, the increase in bone-ALP was 31.5%, 
that of CTX was 105.4%and the decrease in BMD parameters 
was signiﬁ  cant both at lumbar spine (−2.37%, p = 0.05) and 
at femoral neck (−1.24%, p = 0.05) (Gonnelli et al 2007). The 
larger IES study described that in the ﬁ  rst 6 months after the 
switching from tamoxifen to exemestane BMD decreased 
by 2.7% at lumbar spine and by 1.4% at total hip. After a median 
follow-up of 58 months and median exposure to exemestane 
of 30 months, 162 (7%) patients in the exemesane group had 
fractures, compared with 115 (5%) patients in the tamoxifen 
group (OR: 1.45; p = 0.003) (Coleman et al 2007). Despite 
its steroidal structure and putative androgenic activity, these 
data conﬁ  rm that, similarly to other AIs, exemestane exerts a 
negative effect on bone.
Bone loss and fracture risk were also analyzed 
retrospectively in a patient-claims database of women with 
early-stage breast cancer and no osteoporosis who received 
an AI (n = 1.354) and those who did not (n = 11.014). The 
prevalence of osteoporosis was 8.7% in the AI group versus 
7.1% in the control group (p = 0.01). Also, the risks for both 
bone loss and fracture were signiﬁ  cantly higher in the AI 
group than in the control group (27% and 21% respectively; 
p = 0.02) (Mincey et al 2006).
Therefore, current data suggest that all the third-generation 
AIs have adverse effects on bone. Also, a recent meta-analysis 
showed that bone fractures were signiﬁ  cantly higher in 
patients receiving AIs than in those who did not (HR 1.50, 
95% CI 1.12–2.02, p = 0.006) (Bria et al 2006). However, 
because of the lack of comparative data, the drawing of any 
conclusions on any clinically relevant differences between 
these agents is difﬁ  cult. Given the expanding use of AIs, a 
diffused screening, an appropriate monitoring and adequate 
treatment strategies are necessary for women candidate to 
AIs. The American Society of Clinical Oncology (ASCO) 
recommends that the breast cancer patients, identiﬁ  ed by their 
history to be at high risk for osteoporosis, should be evaluated 
by BMD measurements (Hillner et al 2003). The high risk 
factors for breast cancer women include age  65 years, age 
60–64 years with other risk factors (eg, family history, body 
weight  70 kg, prior non-traumatic fracture) postmenopausal 
women of any age receiving AIs, premenopausal women with 
therapy associated premature menopause. All women with 
breast cancer at high risk, independently of BMD results at 
baseline, need to repeat the BMD measurement after 1 year. 
The women at low risk need to be clinically monitored annu-
ally for risk status. Therefore, all postmenopausal women 
treated with AIs can be considered at high risk and evaluated 
for BMD annually. In the presence of osteoporosis (BMD 
T score  −2.5) the patients should have pharmacologic 
therapy initiated with an antiosteoporotic drug. A calcium 
vitamin D supplementation is also recommended for all 
women treated with AIs.
Although there is currently no approved treatment or 
any prevention therapy for the aromatase-inhibitor induced 
bone loss, clinical trial evidence indicates that intravenous 
and oral bisphosphonates are effective in maintaining bone 
density in breast cancer patients on hormone therapy and 
with therapy-associated premature menopause. In particular 
iv bisphosphonate zoledronic acid has shown clinical beneﬁ  ts 
in the treatment of bone metastases among patients with solid 
tumors. In a Cochrane review that assessed all approved 
oral and iv bisphosphonates for breast cancer treatment, Clinical Interventions in Aging 2008:3(4) 652
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zoledronic acid produced a greater reduction in the risk 
of skeletal related events with respect to both placebo 
(−41%) and ibandronate, clodronate and pamidronate 
(ranging from −14% to −23%) (Pavlakis et al 2005).
A recent substudy of the Austrian Breast and Colorectal 
Cancer Study Group (ABCSG) has demonstrated that 
zoledronic acid (4 mg iv every 6 months over 3 years) 
was effective in counteracting bone loss in premeno-
pausal women receiving adjuvant endocrine therapy 
(goserelin plus anastrozole) for hormone-responsive breast 
cancer (Gnant et al 2007).
In the Zometa-Femara Adjuvant Synergy Trial (Z-FAST), 
zoledronic acid also appeared to prevent bone loss in 
postmenopausal women with stage I-IIIa estrogen and/or 
progesterone-receptor positive breast cancer receiving 
adjuvant letrozole (n = 602) (Brufsky et al 2007). Three 
hundred and one of those patients received upfront zoledronic 
acid (4 mg iv every 6 months), whereas the other 301 women 
in the delayed arm of the trial received zoledronic acid 
only if their T-score at lumbar spine or total hip decreased 
below −2.0 SD or if they had a clinical fracture. After 1 year 
of zoledronic acid treatment (4 mg iv every 6 months), 
the lumbar spine and total hip BMD increased by 2.0% 
and 1.4% respectively. In contrast, among women in the 
delayed arm of the trial, BMD decreased substantially by 
2.6% and 2.1% at lumbar spine and total hip, respectively 
(Brufsky et al 2007).
Despite these promising data, the use of an aggressive 
preventive strategy using iv bisphosphonates needs to be 
validated by larger randomized studies. In fact in recent years 
there has been an increasing number of reports which suggest 
that the prolonged use of intravenous bisphosphonates 
may be associated with osteonecrosis of the jaw (ONJ), 
an uncommon manifestation characterized by the presence 
of exposed bone in the oral cavity (Weitzam et al 2007; 
Brufsky 2008).
A retrospective analysis in Australia (2004–2005) 
reported a 0.88% to 1.15% frequency of ONJ among patients 
with malignant bone disease from cancer and a frequency 
of only 0.01% to 0.04% among patients with osteoporosis 
receiving a bisphosphonate. Therefore, the frequency of ONJ 
appears to be lower among patients with no malignant bone 
disease compared with patients who have advanced cancer 
(Mavrokokki et al 2007).
A possible alternative in the prevention of bone loss in 
breast cancer women is represented by oral bisphosphonates, 
which are less commonly associated with the development of 
osteonecrosis of the jaw than intravenous bisphosphonates. 
It has recently been reported that oral bisphosphonate 
risedronate prevents anastrozole induced bone loss with an 
increase of BMD at lumbar spine and a decrease of bone 
turnover markers (Confavreux et al 2007).
In conclusion the negative effects of AIs on bone have 
to be taken into account and all women should receive 
lifestyle advice. Aromatase inhibitor-associated bone loss 
may represent a preventable and curable condition, and in 
high risk women a treatment with antiresorptive agents, such 
as bisphosphonates, should be considered.
Effects of AIs on lipids
Large-scale epidemiological studies have shown that high 
serum levels of total cholesterol (TC) and LDL-cholesterol 
(LDL-C) are important risk factors for the development 
of cardiovascular diseases (CVD), and that low serum 
levels of HDL-cholesterol (HDL-C) and hypertriglyceri-
demia (TG) are associated with increased coronary heart 
diseases (CHD), morbidity and mortality. New emerg-
ing risk factors for CHD, including insulin resistance, 
glucose intolerance and prothrombotic state, are an issue 
of growing interest in CVD prevention. Estrogens have 
a protective effect on the lipid proﬁ  le in human subjects, 
and high levels of HDL-C and low levels of LDL-C 
are associated with high estrogen levels. Therefore, the 
reduction of estrogen levels which occur during adjuvant 
therapy for breast cancer may lead to a more atherogenic 
lipid proﬁ  le and increased CHD risk.
The rates of CHD in women after the menopause 
are 2 to 3 times those of premenopausal women of the same 
age and the dramatic decline in estrogen levels during the 
menopause is associated with unfavorable changes in lipid 
proﬁ  le (Rosano et al 1996). Estrogen replacement therapy is 
known to have a mixed effect on serum lipids, resulting in a 
signiﬁ  cant decrease in TC and LDL-C, a favorable increase 
in HDL-C, but an unfavorable increase in TG. Randomized 
controlled trials have demonstrated that estrogen replacement 
therapy causes either no beneﬁ  t or an increased cardiovascular 
risk (Manson et al 2003).
Tamoxifen has demonstrated a favorable effect on lipid 
proﬁ  le in postmenopausal women with a reduction in TC and 
LDL-C levels. After 5 years of treatment with tamoxifen there 
was a signiﬁ  cant change in lipid proﬁ  le in node-negative post-
menopausal women compared with untreated patients: TC, 
LDL-C and lipoprotein(a) decreased, while HDL-C remained 
unchanged (Love et al 1994). An adjuvant study showed that 
after 15 months of tamoxifen treatment there was a signiﬁ  cant 
increase in serum TG levels compared with baseline levels Clinical Interventions in Aging 2008:3(4) 653
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(Liu and Yang 2003). With regard to AIs, current data do not 
allow the drawing of any clear conclusions about the effect 
of these drugs on lipid metabolism.
Data on lipid proﬁ  le were not systematically collected 
in the ATAC trial; however, the prevalence of low grade 
hypercholesterolemia was reported to be 2.6 fold higher in 
patients receiving anastrozole than in those taking tamoxifen 
(ATAC Trialists’ Group 2005).
Most studies on anastrozole in postmenopausal women 
with early breast cancer have shown beneﬁ  cial increases 
in HDL-C and favorable decreases in TG, while variable 
effects on the levels of TC or LDL-C were described 
(Sawada and Sato 2003). In the ITA Trial, the switching to 
anastrozole after 2–3 years of tamoxifen was also associated 
with an increased incidence of lipid metabolism disor-
ders (9.3% vs 4.0%, p = 0.04) with respect to patients receiv-
ing 5 years of tamoxifen treatment (Boccardo et al 2006).
Even the ARNO 95/ABSCG-8 combined analysis did not 
report hypercholesterolemia in women switching to 3 years 
of anastrozole after 2 years of tamoxifen compared to the 
standard 5 years of tamoxifen (Jakesz et al 2005).
With regard to letrozole, this agent caused a deterioration 
of lipid proﬁ  le with an increase of atherogenic risk ratios TC/
HDL-C and LDL-C/HDL-C in postmenopausal women with 
metastatic breast cancer previously treated with tamoxifen 
(Elisaf et al 2001). Instead the MA-17 trial did not document 
any detrimental effect of letrozole on lipid levels, and similar 
frequencies of hypercholesterolemia were observed in the 
placebo and letrozole groups (Goss et al 2005).
The BIG 1–98 trial reported a greater than two-fold increase 
in the incidence of hypercholesterolemia with letrozole 
therapy compared with the tamoxifen (43.6% vs 19.2%, 
respectively); however, over 80% of these were mild and 
did not require treatment (Thurlimann et al 2005). Notably, 
these data were based on single, non-fasting measurement 
of blood cholesterol, and any single event at any time during 
the study resulted in a positive report. For this reason, a valid 
interpretation of these data is difﬁ  cult.
The other AI exemestane has shown a signiﬁ  cant reduction 
of TC and TG, and an unfavorable decrease in HDL-C in a 
small study on postmenopausal women with advanced breast 
cancer (Engan et al 1995). Another study showed only a 
signiﬁ  cant reduction in HDL-C (p   0.001) and apolipopro-
teina A1 (p = 0.004) in women assigned to exemestane with 
respect to the placebo group (Lonning et al 2005).
Exemestane has also been shown to have no detrimental 
effects on serum lipids or atherogenic risk in postmenopausal 
women with metastatic breast cancer (Atalay et al 2004). 
More recently, a comparison of the effect of exemastane 
versus tamoxifen on the lipid proﬁ  le of postmenopausal 
early breast cancer patients was reported in the prelimi-
nary results of the TEAM Greeck substudy at a 12 month 
follow-up (Markopoulos et al 2005). In this study, although 
mean LDL-C levels were higher in the exemestane versus 
the tamoxifen group, triglyceride levels were lower, while 
no difference was reported in total cholesterol or in HDL 
cholesterol. These data seem to suggest that exemestane 
may have a less unfavorable effect on lipids with respect to 
the non-steroidal aromatase inhibitors. In contrast, a recent 
adjuvant study compared postmenopausal women switched 
to exemestane treatment after 2–3 years of tamoxifen with 
the women who continued the 5-year tamoxifen therapy. The 
exemestane treated patients presented a signiﬁ  cant (p   0.01) 
decrease in HDL-C and TG and a signiﬁ  cant increase in 
serum LDL-C, whereas the women who continued tamoxifen 
did not show any signiﬁ  cant changes in lipid parameters 
(Montagnani et al 2007). In this latter study, however, the 
increase in LDL-C could mainly be explained by the loss of 
the positive action of tamoxifen; in fact in the second year 
of the study, no further increase in LDL-C was observed 
(Montagnani et al 2007).
The effects of AIs on body composition in postmenopausal 
women with breast cancer, switched from adjuvant tamoxifen 
to adjuvant exemestane, were also investigated: fat mass 
signiﬁ  cantly decreased by month 12 in the exemestane group, 
but not in the tamoxifen group; the between-group difference 
was statistically signiﬁ  cant (p   0.01) (Francini et al 2006). 
In this latter study the fat free-mass/fat mass ratio signiﬁ  -
cantly (p   0.05) increased in the exemestane group, but not 
in the tamoxifen group. These ﬁ  ndings suggest that switching 
patients to adjuvant exemestane treatment after at least two 
years of tamoxifen may be associated with an advantage over 
continuing adjuvant tamoxifen in terms of body composition. 
Since it is known that exemestane and the other AIs reduce 
circulating estrogen levels, and estrogens have direct effects 
on adipocytes, the authors suggested there may be an associa-
tion between exemestane use, reduced circulating estrogen 
levels and body weight changes (Francini et al 2006).
Overall, the available studies suggest that the differences 
in lipid proﬁ  le between tamoxifen and AIs may be due to the 
lipid-lowering capacity of tamoxifen rather than to increases 
in lipid levels due to AIs. However, the true difference in 
changes of lipid parameters between patients receiving 
tamoxifen and AIs still has to be deﬁ  ned and therefore no 
exact recommendation concerning the monitoring of lipid 
metabolism may at present be given. As a general guideline, Clinical Interventions in Aging 2008:3(4) 654
 Gonnelli and Petrioli
patients should perform a baseline and periodic monitoring 
of the fasting lipid proﬁ  le before starting adjuvant hormonal 
therapy, maintain a correct lifestyle with a healthy diet and 
regular exercise, and assume medications useful for the treat-
ment of pre-existing hypercholesterolemia.
Effects of AIs on cardiovascular 
events
Even though lipids are important risk factors, the relationship 
between hormone related changes in lipid proﬁ  le and the 
development of CVD events is unclear. Although most of 
the studies demonstrated that tamoxifen has a favorable 
effect on lipid proﬁ  le, this did not seem to translate into 
a beneﬁ  cial effect on the development and progression 
of CVD. A meta-analysis reported that tamoxifen signiﬁ  -
cantly decreased myocardial infarction deaths but did not 
signiﬁ  cantly reduce the myocardial infarction incidence 
(Braithwaite et al 2003). The 15-year survival update from 
the Early Breast Cancer Trialists Collaborative group 
meta-analysis found a borderline significance regard-
ing reduced mortality from heart disease in breast cancer 
patients receiving tamoxifen compared with a control 
group (120 vs 132 p = 0.06) (Clarke 2006).
The effect of AIs on cardiovascular risk is less deﬁ  ned, 
since long-term studies are needed to evaluate the develop-
ment of cardiovascular events as a consequence of treatment 
with these agents. Some data have been drawn from studies 
using anastrozole and letrozole in the advanced setting. In 
fact anastrozole-treated patients showed a signiﬁ  cant decrease 
in thromboembolic events, including venous thromboembolism, 
coronary ischemic and cerebrovascular events compared with 
tamoxifen (Nabholtz et al 2000; Mouridsen et al 2001). In the 
ATAC study, anastrozole resulted in a clinically signiﬁ  cant 
reduction in the incidence of cerebrovascular events (2.0% vs 
2.8%) and thromboembolic events (2.0% vs 4.5%) in comparison 
with tamoxifen (ATAC Trialists’ Group 2005). In the same study 
a non signiﬁ  cant increase in ischemic cardiovascular diseases 
was associated with anastrozole therapy. Data on cardiovascular 
diseases were not reported in detail in the ABCSG/ARNO Trial, 
but there was no difference in the incidence of myocardial infarc-
tion between the anastrozole arm and the tamoxifen arm (Jakesz 
et al 2005). The overall reported incidence of cardiovascular 
events in BIG 1–98 was similar in the two groups (5.5% and 
5% for letrozole and tamoxifen respectively) (Coates et al 2007). 
However, in BIG 1–98 there was an excess of severe events 
(grades 3–5) of both heart failure and ischemic heart disease in 
the letrozole arm with respect to the tamoxifen arm (1.0% vs 
0.6% and 2.2% vs 1.7%, respectivaly) (Coates et al 2007).
A recent reanalysis of the cardiovascular adverse events 
of BIG 1–98 trial has reported that at a median follow-up 
time of 30.1 months there was a similar overall incidence 
of cardiac adverse events (letrozole 4.8%; tamoxifen 4.7%) 
but more grade 3 to 5 cardiac adverse events on letrozole 
(letrozole 2.4%; tamoxifen 1.4%; p   0.001) and more 
overall tromboembolic events on tamoxifen (tamoxifen 3.9%; 
letrozole 1.7%; p   0.001) (Mouridsen et al 2007).
The effect of prolonging letrozole treatment beyond 5 years 
is currently being addressed in the MA.17R rerandomization 
study in which patients who remain disease-free after 
completing 5 years of letrozole extended adjiuvant therapy 
are randomized to letrozole or placebo for a further 5 years. 
This study will provide further data on safety issues 
associated with long-term use of letrozole (Goss et al 2003; 
Goss et al 2005).
A non-signiﬁ  cant increase in the incidence of cardio-
vascular disease was also reported in patients switching to 
exemestane in the IES trial, including a 2.5-fold increase in the 
number of myocardial infarctions (Coombes et al 2007).
However, in this trial, as well as other postadjuvant 
or switching studies, it is difﬁ  cult to deduce whether the 
cardiovascular adverse events observed may be attributed, 
at least in part, to the effects of prior tamoxifen or whether 
these events are a true effect of the AIs.
Overall, the current available ﬁ  ndings suggest that the 
impact on CVD of the long-term use of AIs is still to be clari-
ﬁ  ed. Nevertheless, in the above mentioned trials deﬁ  nitions of 
cardiac and ischemic disease were not consistently deﬁ  ned, 
follow-up was short ( 10 years), and risk factors for coro-
nary disease (including lipid proﬁ  les) were not systematically 
documented. However, when starting a treatment with AIs it 
is important to determine the presence of associated comor-
bidities, such as diabetes mellitus, hypertension, smoking, 
and/or the use of anthracycline-based chemotherapy, which 
may increase the risk of developing cardiomyopathy and 
symptomatic heart failure or other cardiovascular events. 
Therefore, when treating breast cancer patients, oncologists 
should correct cardiovascular risk factors as is done with 
patients who do not have breast cancer. Moreover, phy-
sicians should assess cardiovascular risk, monitor and 
treat patients already diagnosed at risk for coronary heart 
disease, according to established guidelines (Winer et al 
2004; Ponzone et al 2008). Another point to consider is that 
the relationship between lipid proﬁ  les, hormonal status, 
and cardiovascular risk is not always clear. Lipids, as risk 
factors, are intermediate end points and may not correlate 
with the clinically relevant end points of the incidence of Clinical Interventions in Aging 2008:3(4) 655
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cardiovascular events in long-term studies. To sum up, AIs 
are associated with lower thrombotic risk when compared 
with tamoxifen, while the possible unfavorable balance of 
AIs on cardiovascular risk needs to be conﬁ  rmed.
Effects of AIs on the musculoskeletal 
system
Clinical experience suggests that the treatment with AIs is 
associated with a novel musculoskeletal side effect consist-
ing of an arthralgia syndrome which sometimes can be a 
reason for discontinuation of AIs treatment. Arthralgia is 
deﬁ  ned as pain or stiffness in the joints, which in patients 
treated with AIs is not caused by arthritis, the typical onset 
of AIs associated arthralgia is within 2 months of treatment 
initiation (Burstein 2007). All the major adjuvant trials of AIs 
have reported the incidence of musculoskeletal symptoms 
or asked directly about arthralgia. Therefore, the reported 
incidence of arthralgia syndrome reﬂ  ects different deﬁ  nitions 
of symptoms and is markedly different in individual studies. 
In fact in the ATAC trial there was a signiﬁ  cant increase 
in arthralgias in the anastrozole arm when compared to 
the tamoxifen arm (35.6% vs 29.4%; p   0.001) (ATAC 
Trialists’ Group 2005). Also, MA 17 trial reported an 
increased frequency of arthralgias in women treated with 
letrozole with respect to those in the placebo arm (25.3% vs 
20.6%; p   0.001) (Goss et al 2005). Finally, the IES study 
conﬁ  rmed that arthralgias were more frequent in the exemes-
tane group (20.6%) (Coombes et al 2007). Even though 
the true etiology of AIs-associated arthralgia syndrome is 
not known, several studies have shown a link between low 
serum levels of estrogen and arthralgias. The natural hypoes-
trogenemia of menopause is also associated with arthralgia, 
which can be ameliorated with hormone replacement therapy 
(HRT) or exacerbated with AIs treatment. Moreover, it 
is known that estrogens regulate inﬂ  ammatory cytokines 
and enhance nociception at the level of the central nervous 
system. Although it is clear that AIs worsen arthralgias com-
pared with either placebo or tamoxifen, the overall impact 
on quality of life and associated morbidity still needs to be 
determined (Burstein 2007; Coleman et al 2008).
Conclusions
The third-generation aromatase inhibitors (AIs), letrozole, 
anastrozole and exemestane, are now widely accepted as 
optimal adjuvant treatment for postmenopausal women with 
early breast cancer. This means that individual patients will 
be exposed to these agents for longer durations, making it 
increasingly important to establish their long-term safety. 
This review focused on the effects of AIs on bone 
metabolism, lipid proﬁ  le, and CVD. Despite the lack of 
comparative studies, current data suggest that all the third 
generation AIs may have adverse effects on bone, with reduc-
tion in BMD and an increase in the rate of bone fractures. 
However, aromatase inhibitor-associated bone loss may 
represent a preventable and curable condition, and a treatment 
with antiresorptive agents, such as bisphosphonates, should 
be considered in high risk women. With respect to tamoxifen 
AIs present lower thrombotic risk but a less favorable impact 
on lipid proﬁ  le. However, the true impact on CVD of the 
long-term use of AIs still remains to be clariﬁ  ed. Even though 
experimental and clinical data suggest that different AIs may 
have a different impact on fracture and cardiovascular risk, 
at present, no consensus exists as to whether the best AI for 
individual patients could be chosen.
To sum up, as a general guideline, it may be recommended 
that patients undergo BMD and lipid proﬁ  le evaluation before 
and during adjuvant therapy with AIs, maintain a correct 
lifestyle with a healthy diet and regular exercise, and assume 
medications useful for managing pre-existing osteoporosis 
and hypercholesterolemia.
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